ロード中...
Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines
BACKGROUND: Approximately 80% of patients with osteosarcoma harbor subclinical pulmonary micrometastases at diagnosis. Conventional chemotherapy includes methotrexate, doxorubicin, and cisplatin (MAP); however, this regimen and thus overall survival (60%-70%) have remained largely unchanged for 30 y...
保存先:
| 出版年: | Clin Orthop Relat Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6437591/ https://ncbi.nlm.nih.gov/pubmed/29481344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11999.0000000000000059 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|